British Columbia Centres for Substance Use and Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6 Canada; School of Medicine, University College Dublin, Health Sciences Centre, Belfield, Dublin 4, Ireland; Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.
British Columbia Centres for Substance Use and Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6 Canada.
Drug Alcohol Depend. 2018 May 1;186:182-186. doi: 10.1016/j.drugalcdep.2018.01.027. Epub 2018 Mar 23.
We sought to examine the factors associated with discontinuation of MMT among persons on methadone who use alcohol.
We evaluated the impact of drug-related and other factors on discontinuation of MMT among persons enrolled in MMT and who reported any use of alcohol versus those who were enrolled in two community-recruited prospective cohorts of people who use illicit drugs (PWUD). Extended Cox models with time-dependent variables identified factors independently associated with time to first MMT discontinuation.
Between December 2005 and 2015, 823 individuals on MMT who also reported using alcohol at least once were included in these analyses. During the study period, 391 (47.5%) discontinued methadone. Daily heroin injection (Adjusted Hazard Ratio [AHR] = 2.67, 95% Confidence Interval [CI]: 2.10-3.40) and homelessness (AHR = 1.42, 95% CI: 1.10-1.83) were positively associated with MMT discontinuation, whereas receiving other concurrent addiction treatment in addition to MMT (AHR = 0.07, 95% CI: 0.05-0.08), as well as >60 mg methadone dose (AHR = 0.48, 95% CI: 0.39-0.60), Hepatitis C virus seropositivity (AHR = 0.65, 95% CI: 0.47-0.90), and HIV seropositivity (AHR = 0.72, 95% CI: 0.57-0.91) were negatively associated with MMT discontinuation. Any/heavy alcohol use was not independently associated with MMT discontinuation.
This study reinforces the known risks of continued heroin injection and homelessness for MMT discontinuation among individuals who also consume alcohol and highlights the protective effect of both MMT dose and receipt of concurrent addiction treatment.
我们旨在研究与接受美沙酮维持治疗(MMT)且同时使用酒精的患者中断 MMT 治疗相关的因素。
我们评估了药物相关因素和其他因素对 MMT 中断的影响,研究对象为接受 MMT 治疗且至少报告过一次使用酒精的患者,以及参加两个社区招募的非法药物使用(PWUD)前瞻性队列的患者。采用具有时间依赖性变量的扩展 Cox 模型,确定与首次 MMT 中断时间相关的独立因素。
2005 年 12 月至 2015 年期间,共有 823 名接受 MMT 治疗且至少报告过一次使用酒精的患者纳入本研究。研究期间,391 名(47.5%)患者中断了美沙酮治疗。每日注射海洛因(调整后的危害比[AHR] = 2.67,95%置信区间[CI]:2.10-3.40)和无家可归(AHR = 1.42,95%CI:1.10-1.83)与 MMT 中断呈正相关,而除 MMT 外同时接受其他成瘾治疗(AHR = 0.07,95%CI:0.05-0.08)、美沙酮剂量>60mg(AHR = 0.48,95%CI:0.39-0.60)、丙型肝炎病毒血清阳性(AHR = 0.65,95%CI:0.47-0.90)和 HIV 血清阳性(AHR = 0.72,95%CI:0.57-0.91)与 MMT 中断呈负相关。任何/大量饮酒与 MMT 中断无关。
本研究证实了继续注射海洛因和无家可归对同时使用酒精的 MMT 患者中断治疗的已知风险,并强调了美沙酮剂量和同时接受成瘾治疗的保护作用。